This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This month’s announcement that Alphabet’s Isomorphic Labs, led by the talented and charismatic Deepmind co-founder Demis Hassabis, had inked discovery collaboration deals with both Lilly and Novartis was just the latest indication that AI-enabled pharma R&D was ready for the big time. Billions of dollars have been invested in companies promising to “revolutionise pharma R&D” through the application of artificial intelligence – but it is now clear that global pharma companies, and not ju
Since a landmark paper in 2022, drugmakers have begun nearly a dozen trials of cell therapies for lupus, with more set to start. Here’s why their efforts are worth watching.
TUESDAY, Jan. 30, 2024 -- The maker of a drug used to treat ADHD and narcolepsy has recalled one lot of the medication after a pill mixup was discovered.The recall notice, issued by Azurity Pharmaceuticals Inc., states that one lot of Zenzedi.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Seong Ho Hong, Anand Divakaran, Akane Osa, Oscar W. Huang, Ingrid E. Wertz, and Daniel K. Nomura ACS Chemical Biology 2024 DOI: [link] Targeted protein degradation with proteolysis targeting chimeras (PROTACs) is a powerful therapeutic modality for eliminating disease-causing proteins through targeted ubiquitination and proteasome-mediated degradation.
Trees are struggling to sequester heat-trapping carbon dioxide (CO2) in warmer, drier climates, meaning that they may no longer serve as a solution for offsetting humanity's carbon footprint as the planet continues to warm, according to a new study.
349
349
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Trees are struggling to sequester heat-trapping carbon dioxide (CO2) in warmer, drier climates, meaning that they may no longer serve as a solution for offsetting humanity's carbon footprint as the planet continues to warm, according to a new study.
TUESDAY, Jan. 30, 2024 -- The first new kind of pain medication in over two decades could be on the horizon for patients, with promising results announced Tuesday from a company trial. For now, the drug from Vertex Pharmaceuticals is called VX-548.
Yizhen Jin , Sadhan Jana , Mikail E. Abbasov , Hening Lin bioRxiv 2024.01.22.576576; doi: [link] The emerging antibiotic resistance requires the development of new antibiotics working on novel bacterial targets. Here, we reported an antibiotic discovery workflow by combining the cysteine-reactive compound library phenotypic screening with activity-based protein profiling, which enables the rapid identification of lead compounds as well as new druggable targets in pathogens.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
THURSDAY, Feb. 1, 2024 -- Certain copycat eyedrops may be contaminated and could give users an antibiotic-resistant eye infection, the U.S. Food and Drug Administration warned Wednesday.The packaging for South Moon, Rebright and FivFivGo eyedrops.
Mir, M.H., Parmar, S., Singh, C. et al. Nat Commun 15 , 859 (2024). [link] Proteins labelled site-specifically with small molecules are valuable assets for chemical biology and drug development. The unique reactivity profile of the 1,2-aminothiol moiety of N -terminal cysteines ( N -Cys) of proteins renders it highly attractive for regioselective protein labelling.
It's an achievement with important implications for scientists studying the brain and working on treatments for a broad range of neurological and neurodevelopmental disorders, such as Alzheimer's and Parkinson's disease.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
The FDA is reviewing the companies’ application for a “tumor agnostic” indication for their drug Enhertu, which would break new ground for antibody-drug conjugates.
TUESDAY, Jan. 30, 2024 -- Opdivo, one of the new generation of immunotherapy cancer treatments, appears to help kidney cancer patients equally well when given as a quick injection versus the current method of intravenous delivery, a new study.
Mast cell stabilizers including disodium cromoglycate (DSCG) were found to have potential as the agonists of an orphan G protein-coupled receptor, GPR35, although it remains to be determined whether GPR35 is expressed in mast cells and involved in suppression of mast cell degranulation. Our purpose in this study is to verify the expression of GPR35 in mast cells, and to clarify how GPR35 modulates the degranulation.
Researchers have discovered a change in what scientists already knew about global warming dynamics. It had been widely accepted since the 1950s that global temperature rises were not consistent throughout the day and night, with greater nighttime warming being observed. However, the recent study reveals a shift in dynamics: with greater daytime warming taking place since the 1990s.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
MONDAY, Jan. 29, 2024 -- Five of eight British children who received human growth hormone from the pituitary glands of deceased donors went on to develop early-onset Alzheimer's disease many decades later, researchers report.Researchers at.
Guillaume Compain, Clément Monsarrat, Julie Blagojevic, Karl Brillet, Philippe Dumas, Philippe Hammann, Lauriane Kuhn, Isabelle Martiel, Sylvain Engilberge, Vincent Oliéric, Philippe Wolff, Dominique Y. Burnouf, Jérôme Wagner, and Gilles Guichard JACS Au 2024 DOI: 10.1021/jacsau.3c00572 Peptide-based covalent inhibitors targeted to nucleophilic protein residues have recently emerged as new modalities to target protein–protein interactions (PPIs) as they may provide some benefits over more classi
Fake news works for wallabies and elephants. Herbivores can cause substantial damage to crops or endangered or protected plants, with traditional methods to deter foraging lethal, expensive or ineffective. Biologists are now using aromas from plants naturally repellent with remarkable success to deter the animals.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
MONDAY, Jan. 29, 2024 -- Following a recall of millions of its breathing machines that began in mid-2021, Philips Respironics announced Monday that it would halt sales of all such machines within the United States.The machines include continuous.
Skye Montoya et al. Science 383 , eadi5798 (2024). DOI: 10.1126/science.adi5798 Structured Abstract INTRODUCTION Bruton’s tyrosine kinase (BTK) is a nonreceptor kinase in the B cell receptor (BCR) signaling cascade critical for B cell survival. As such, chronic lymphocytic leukemia (CLL) and other B cell cancers are sensitive to inhibition of BTK. Covalent and noncovalent inhibitors of BTK have revolutionized the treatment of these cancers.
Scientists developed a new method to map exactly how a fungus works with leafcutter ants in a complex microbial community to degrade plant material at the molecular level. The team's insights are important for biofuels development.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
165 
Let's personalize your content